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Objective: Given the reported increased rates of physical morbidity and higher mor-
tality rates among people with severe mental illness (SMI) (schizophrenia and severe
mood disorders), with a life expectancy shorter of 15-20 years with respect to the
general population, the aim of this paper was to call attention to the problem of can-
cer in SMI.
Methods: We conducted a narrative review of the most significant papers published
in the areas of cancer screening, incidence, mortality and palliative care in SMI.
Results: Data from the literature confirm disparities in screening (eg, mammography;
pap-smear test; colorectal cancer screening) and prevention (eg, clinical breast exami-
nation; smoking cessation). The incidence of cancer was found to be variable with a
portion of the studies reporting a higher prevalence while others a similar or a lower
prevalence of cancer compared to the general population. A lower percentage of
patients with SMI received proper cancer treatment resulting in survival after cancer
diagnosis significantly worse than people without SMI. Likewise, end-of-life care has
been shown to be lacking with poorer levels of physical, psychological and
spiritual care.
Conclusions: The problems of stigma and discrimination, poorer dignity, poorer
health behavior, lack of integration in health-care services for people with SMI needs
to be addressed and solved in cancer care. Psycho-oncology has a very specific and
mandatory role in integrating the recommendation of the World Health Organization
to improve the links between oncology and mental health settings for more specific
psycho-oncology programs addressed for this vulnerable segment of the population.
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1 | INTRODUCTION
Worldwide, the prevalence of psychiatric disorder regards 1 out of
4 people with about 450 million having severe mental illness (SMI), of
whom 300 million are living with depression, 21 million with schizo-
phrenia and 46 million with bipolar disorders,1 with similarities
between North America2 Europe3 and other parts of the world,
including Asian-Pacific areas.4 In fact, a survey in Europe3 involving
28 European Union countries plus Norway and Switzerland, also con-
firms that about 38% of residents of the EU, or around 165 million
people, are affected by a mental illness at some point in any given
year and that it is the challenge of the 21st century. COVID-19 cer-
tainly has added to the detection and service delivery but the prob-
lems with the SMI and cancer care have been long standing. In fact,
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only about one-quarter of those with a mental illness in Europe
received any treatment, and only about 10% had “nationally ade-
quate” care and integrated medical, social, employment and psycho-
logical provision which is the key for recovery.3
Besides the several implications of SMI in terms of poor quality of
life and level of functioning, problems at work, social integration and
stigma, the last two decades have seen much of the research focused
on physical health, not on the integration of SMI and cancer care.5,6
One of the most important and recognized problems is that people
with SMI, especially schizophrenia, bipolar disorders and severe
depressive disorders, have both an increase rate of morbidity because
of somatic disorders and higher mortality rates, aside from cancer.7-9
The provisional conclusions of these studies is that there is sufficient
evidence that people with SMI are less likely to receive standard
levels of care for most diseases, such as diabetes and heart disease
associated with lifestyle factors. They are less likely to be considered
for screening such as for mammography or prostate surveillance; less
likely to receive baseline testing of numerous important physical
parameters such as obesity, high blood pressure; so that access to and
quality of health care remains to be improved for individuals with
SMI.10 This is responsible for a shorter life expectancy of 15-20 years
compared to the general population. This has brought clinical scien-
tists to underline that the contravention of the international conven-
tions for the right to health for the poorer physical healthcare and
premature mortality is significantly worsened in people with SMI, and
is a worldwide problem deserving attention and quick solutions.11
Whereas most studies have pointed attention to cardiovascular
disease and related disorders, including hypertension, diabetes and
metabolic syndrome,12,13 cancer has been also considered an impor-
tant topic to be taken into account in research and clinical
practice.14-16
2 | PREVENTION ISSUES AND SCREENING
FOR CANCER IN PEOPLE WITH SMI
Disparities in health services provided to people with SMI have been
documented for preventive services in general. This is true also as far
as prevention and screening for cancer.
Regarding mammography for example, preliminary data on
women with mental illness and/or substance abuse, regardless of
severity, showed that there was a risk for underscreening.17 Other
research on patients with SMI indicate that women with mental illness
are 32% less likely to undergo at least one screening mammography
and among those who received at least one screening mammography,
fewer women with mental illness received screening mammography
on an annual basis.18 These data are in line with a further study show-
ing that women with a mental illness are at risk for not adhering to
recommended routine breast cancer screening and may require more
intensive efforts to achieve optimal rates of recommended breast can-
cer screening.19 More recently, by examining different types of mental
disorders (ie, mood disorders, depression, SMI, distress and anxiety
conditions) Mitchell et al,20 identified 24 studies reporting breast
cancer screening practices in a large sample of 715 705 women with
mental illness. Their pooled meta-analysis demonstrated significantly
reduced rates of mammography screening in women with mental ill-
ness, especially mood disorders and schizophrenia.
Similar results were found as far as screening for cervical cancer
with studies indicating that women with schizophrenia were less likely
to have a Pap test (58.8% vs 67.8%) compared to all other women.21
A further review confirmed substantial evidence in the literature for
disparities in breast and cervical cancer screening rates among women
with SMI.22
For lung cancer, it has been shown that patients with SMI have
less access to smoking cessation and cancer screening programs
because of lack of clinician expertise tailoring communication about
cancer care and tobacco cessation, and the fragmentation of mental
health and cancer care.23 Also treatment is poorer when lung cancer
has been diagnosed.24 Likewise, a study in Hong Kong indicated a low
cancer screening utilization for several conditions, including mammog-
raphy; clinical breast examination; pap-smear test; prostate examina-
tion; and colorectal cancer screening.25
A very large and recent metanalysis involving almost 5 million
people (501 559 patients with mental illness, and 4 216 280 controls)
from 47 publications and involving many possible mental illnesses
(ie, schizophrenia or schizoaffective or psychosis, depression or bipo-
lar disorder or mania, eating disorder or anorexia nervosa or bulimia
nervosa or binge eating disorder, obsessive-compulsive disorders,
post-trauamtic stress disorder, anxiety disorder or panic disorder) pro-
vided a global overview of the problem. Data included studies relative
to screening for cancer with results showing that screening was signif-
icantly less frequent in people with any mental disease compared with
the general population for breast cancer, cervical cancer, and prostate
cancer, but not for colorectal cancer.26
3 | INCIDENCE OF CANCER AND CANCER
MORTALITY IN PEOPLE WITH SMI
The problem of the incidence of cancer and cancer mortality among
patients with SMI is still controversial, with some studies reporting a
higher prevalence while others a similar or a lower prevalence. A
series of reviews of data and meta-analyses which are available have
tried to shed some light in this area. By analyzing the data from over
6000 female patients with schizophrenia from 13 studies in compari-
son to age matched general populations from the relevant country
from 1986 to 2008, Bushe et al27 reported widely discrepant results,
ranging from 52% increase in risk to 40% decrease, with six of 13 stud-
ies showing an increased or marginally increased incidence of breast
cancer. In a further meta-analysis of 12 cohort studies that included
125 760 women and in which conventional methods of meta-analysis
had been used, schizophrenia in women was associated with an
increased breast cancer incidence compared with the general popula-
tion.28 A further recent meta-analysis of studies29 showed that
compared with general populations, the prevalence rates of prostate
and colorectal cancer in male patients with schizophrenia are lower,
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and lung cancer prevalence is higher in female patients, while no
difference was found in a different meta-analysis for lung cancer.30
There are also data indicating that the incidence of colon cancer was
higher among people with schizophrenia in comparison with people
with bipolar disorders or the general population,31 while a different
Northern European population-based study (time span 1990-2013 for
1 424 829 person-years of follow-up) showed a higher risk for female
breast cancer, lung cancer, esophageal cancer and pancreatic cancer
and a lower risk of prostate cancer,32 as already reported in a previous
study.33
It is possible that there might be protective factors or risk factors
among patients with schizophrenia that relate to specific cancers.
With respect to this, changes in endocrine hormones caused by anti-
psychotic medications, familial or genetic factors (eg, tumor suppres-
sor gene p53, enhanced natural killer cell activity, angiogenesis, or
DNA repair mechanisms), reduced parity and hyperprolactinaemia
may be factors contributing to determine such contradictory
results.34-36
Regarding bipolar disorders, elderly people are reported to have a
delay in receiving specific cancer treatment, although no studies have
investigated treatment outcomes.37 Also, a study carried out in Israel
showed an enhanced cancer risk for bipolar disorder both in men
(Standardized Incidence Ratio, SIR 1.59) and women, (SIR 1.75)38 As
stated by Howard et al,39 when interpreting these results, it is useful
to consider the effect of missing cancer diagnoses, short-ended life
expectancy, the characteristics of health-service contexts, behavioral
risk factors, and the possibility that genetic or drug effects can influ-
ence the results of the studies. It is mandatory for example, to control
for age and sex in incidence studies since while SMI, including schizo-
phrenia and bipolar disorders, are more common in young adults and
are associated with a shortened life, most cancers are diagnosed in
patients older than 60 years and the cancers affecting men and
women differ. Also, patients with SMI have higher overall mortality
rates, particularly from suicide and unnatural causes at younger ages.
With these caveats, mortality for cancer is demonstrated to be
higher among people with SMI. For example, in a prospective study
Chou et al,40 showed that among 1145 patients with schizophrenia
and 5294 controls, the incidence of breast cancer was lower (1.93%
vs 2.97%), although the mortality rate among patients with schizo-
phrenia was higher than that of the control group. Similar results were
found among patients with schizophrenia and lung cancer,41 who are
reported not having received stage-appropriate treatment, resulting in
poorer outcomes.24
With respect to prostate cancer, a study of 49 985 patients with
locoregional high-grade (nonmetastatic) cancer showed that having a
SMI (bipolar disorder, schizophrenia, and other psychotic disorders)
was associated with reduced odds of receiving surgery or radiation
concurrent with hormone therapy as initial treatments in the year
after diagnosis. Additionally, SMI was associated with higher hazard
of 5-year cancer-specific death after accounting for competing risks
of non-cancer death.42 Again, in an Australian study, although the inci-
dence of cancer was not higher than in the general population, psychi-
atric patients were more likely to have metastases at diagnosis and
less likely to receive specialized interventions, with a greater case
fatality.43 Similar results were found in a study of 16 636 elderly
women in which patients with comorbid anxiety and depression had
an increased risk for diagnosis delay of ≥90 days from symptom rec-
ognition, and those with severe mental illness had an increased risk
for initial treatment delay of ≥60 days from diagnosis.44 More
recently, in a large Danish study on 56 152 women with early-stage
breast cancer diagnosed in 1995-2011, patients with schizophrenia or
related disorders had a higher likelihood to not be provided proper
cancer guideline treatment and to have a survival after breast cancer
significantly worse than that of women without SMI.45
4 | PALLIATIVE CARE IN PEOPLE
WITH SMI
The existence of disparities in health and health care between
patients with schizophrenia and/or SMI and patients without a diag-
nosis of mental illness is extremely important also in end-of-life care.
In concert with data underlining the problems of the stigma, poverty,
lack of family support and social isolation, patient-level factors includ-
ing cognitive impairment, psychiatric disabilities and chronicity,46 end-
of-life care has been shown to be lacking for patients with schizophre-
nia and/or SMI.47
In one of the first studies conducted in a palliative care setting,
Chochinov et al48 found that compared to their matched cohort,
Canadian patients with schizophrenia were less likely to see specialists
other than psychiatrists, less likely to be prescribed analgesics, and
less likely to receive palliative care. They also were much more likely
to die in nursing homes where optimal physical, psychological and
spiritual care is possibly less optimal than in palliative care units.49
In a further Australian study,50 people with schizophrenia in the
last year of life were less likely to be admitted to hospital and access
community-based specialty palliative care, but more likely to attend
emergency departments if male. Community-based specialist palliative
care was associated with increased rates of hospital admissions. In
general, what emerges is that stigma affects quality of care and access
to care; that there are problems related to consent and capacity for
the patients to make end-of-life care decisions or to appoint substi-
tute decision makers; thta there is an urgent need for better practices
for psychosocial interventions, pharmacology, family and health-care
collaborations, including setting, communication, provider education,
and access to care.51 These data were more recently confirmed by
other studies in Taiwan52 and France.53 The latter was carried out on
2481 patients with schizophrenia and 9896 matched controls. The
authors found that patients with schizophrenia were more likely to
receive palliative care in the last 31 days of life and less likely to
receive high-intensity end-of-life care (eg, chemotherapy and surgery),
were more likely to die younger and had a shorter duration between
cancer diagnosis and death than controls.
Looking at the qualitative issues related to patients with SMI, cli-
nicians have indicated several problems to be addressed. A first regard
information processing and communication in part determined by
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cognitive impairment and lack of insight secondary to SMI. A second
issue has to do with the problem of identify carers in the home envi-
ronment because of previous family disruption or living in
sharehouses, alone or being homeless. Also it has to be underlined the
lack of experience, lack of adequate educational resources and services,
lack of training, policies or guidelines, or fear and ignorance about
SMI among health carers. Last, there are common preoccupations
related to the assumption that the patient will be unmanageable,
because identifiable institutional or community care staff to provide
adequate care are considered insufficient.54 A recent review55 indicated
that an increased awareness of potential healthcare disparities in this
population, creative approaches in multidisciplinary care, and provision
of adequate palliative services and resources can enhance end-of-life
care in schizophrenia.
5 | POSSIBLE MECHANISMS INVOLVED IN
THE PROBLEM
One of the most significant debates regarding poor health care in peo-
ple with SMI is related to the problem of stigma leading to the prob-
lem of discrimination and reduced expression of human rights.56-58
Available research in psychiatric settings indicates that stigma consists
of both the auto perception of one-self as stigmatized and different
from others (self-stigma, as the internalization of a negative stereo-
type that the person applies to oneself)59 and the stigma imposed by
society (social stigma, as the series of stereotyped beliefs, prejudices
and discriminatory attitudes). Elsewhere60 we have considered the
dimension of stigma as the expression of the other side of dignity,
where also it is possible to distinguish a self-related sense of personal
value and dignity (intrinsic dignity) and a reciprocal and interpersonal
experience of dignity related to what others provide us in terms of
value and dignity (extrinsic dignity). Being seen as an equal human
being, with the potential to experience self-worth, meaning and pur-
pose are key factors to maintaining dignity, despite suffering the con-
sequences of mental illness and having to fight for one's rights.61,62
Therefore, throughout the continuum of cancer care, the stigma of
mental illness and poor dignity are factors influencing the manage-
ment of the disease.
In the context of cancer, Irwin et al63 have suggested that interre-
lated patient-based, provider-based, and systems-based factors,
influenced by mental health stigma, may impact cancer prevention,
diagnosis, treatment, and end of life care. More specifically the
authors consider that disparities in cancer care for patients with
schizophrenia (but it can be extended to others with SMI) is derived
by the inter-relationship between these factors. From one side,
patient's inappropriate affect, positive or negative psychotic symp-
toms, cognitive symptoms (eg, impaired attention and executive func-
tion), disorganized behavior, dysfunctional coping (eg, pathological
denial), and poor health behavior (eg, smoking, substance use and/or
abuse, poor adherence) intervene to create part of the problem. It is
demonstrated that the tendency to avoid the health care system, to
minimize or not understand physical symptoms because of poor
insight to not cooperate with caregivers, cause a delay in diagnosis
and presentation at cancer centers with late-stage cancer.64,65 Also
functional impairment of people with SMI is one pf the most signifi-
cant predictor of lower screening rate.66 On the other side, the diffi-
culty of health-care providers (eg, GPs, oncologists, nurses) in relating
to patients with poor functioning, and showing psychiatric symptoms
that are unfamiliar and incomprehensible to the team, the fear of vio-
lent behavior or suicide risk, and the several prejudices on SMI and
its un-treatability can determine a second part of the problem. Finally,
the fragmentation of health care services, the difficulty in creating a
whole-person centered approach, the tendency of psychiatry and
somatic medicine to work in a separate or non-integrated way are a
third cause of the problem. All the three aspects are subsumed under
the concept of stigma. This in turn negatively influences cancer care,
from prevention and screening, to early diagnosis, treatment and
symptom management, as well as end-of-life care, with an impact in
reducing both quality of life and survival. Therefore, it is important to
improve the area of education and training, including communication
skills and assessment and management of emotions and psychiatric
symptoms when dealing with people with SMI in order to increase the
quality of their cancer care, and physical health in general.67
6 | DISCUSSION
There are several considerations to be mentioned in the analysis we
have done about the problem of cancer care among people with SMI.
One of the most important findings emerging from the psycho-
oncology literature concerning people with SMI is that there are now
significant data indicating major disparities in screening and treatment
for cancer for this vulnerable population compared with that of the
general population. A second issue is that people with SMI are less
likely to receive optimal treatment after diagnosis with poorer cancer-
specific prognosis and lower survival time.
These data are in line with what has been shown in the literature
regarding poorer physical health in patients with SMI and the need, as
indicated by Tosh et al,68 that physical health can be the target of
intervention in both psychiatry and medicine in general, in order to
favor the access to health services which, in turn, facilitates longer-
term benefits, such as reduced mortality or morbidity. On the other
hand, the WHO Comprehensive Mental Health Action Plan, endorsed
by the World Health Assembly in 2013, has repeatedly outlined the
need that Member States and organizations (eg, Refs.69,70) develop
and implement effective policies, strategies and plans to improve the
health, both physical and mental, of people living with SMI. The WHO
itself indicates in fact actions that can be taken such as: creating pro-
tocols for physical and mental health needs of patients in the areas of
prevention, identification, assessment and treatment; improving
access to general health services through the integration of physical
and mental health services; working to overcome the stigma associ-
ated mental illness and discrimination.
With specific reference to cancer, in order to decrease the early
mortality of patients with SMI, especially schizophrenia, Chou et al71
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have proposed a series of steps to be rapidly taken by the health care
systems, namely:
1. enhance early detection and early treatment, such as increasing
the cancer screening rate for patients with schizophrenia;
2. provide effective, timely treatment and rehabilitation;
3. improve patients' psychiatric symptoms and cognitive impairment;
4. promote healthy behavior in the general population and emphasize
healthy lifestyles in vulnerable populations;
5. act on reducing the stigma of schizophrenia.
Regarding palliative care several recommendations have been
stressed by Woods et al72 who underlined that palliative care needs
of people with SMI are similar to the general population (eg, pain and
symptom control, maintenance of function, enhancement of quality of
life, support for relationships, and the possibility of dying well); that
palliative care must be centered on the needs of the individual person
with SMI basing a therapeutic relationship created by respect, dignity,
hope, and non-abandonment, integrating principles of hospice pallia-
tive care in end-of-life care for people with SMI; that policies and
guidelines to address the needs of this population should be devel-
oped and revised by integrating the systems of care (mental health
care, palliative care, family medicine, social services) for better inter-
vention for people with SMI and their families.
6.1 | Clinical implications
Psycho-oncology has a very specific role in the area of SMI, with a
strong commitment to better understand health inequalities in cancer
care for people with psychiatric disorders and to plan and develop
effective interventions. The time has come to bridge the gap between
stigma and mental illness, and improve the links between oncology
and psychiatry for more specific psycho-oncology programs addressed
to this vulnerable segment of the population. Some interesting experi-
ences have been reported in the area with data demonstrating that
specific tailored screening and management intervention are possible
for patients with severe mental disorders, such as schizophrenia, if
organized in an integrated multidisciplinary way.73,74 With respect to
this, it is therefore important to stress the fact that the introduction
of psycho-oncologists in teams and the establishment of psycho-
oncology departments / units should consider not only a link with
specialties in oncology (eg, medical oncology, hematology, radiation
oncology, surgery, palliative care), or biological sciences (eg, epidemi-
ology, immunology, biology, pathology, genetics), but a more struc-
tured liaison with mental health department.75
6.2 | Study limitations
As a limitation of this study, we conducted a narrative review that had
the aim to report the main data and results from significant studies in
the area of the relationship between SMI and cancer. Therefore, more
complete searches of usual databases (e.g. PubMed, CINAHL, Embase,
and PsycInfo) on the different topics of this area (screening for can-
cer, risk of developing the disease, treatment, outcome and mortality)
are necessary. Also the recommendations for systematic reviews
should have been followed.
7 | CONCLUSION
With all this as background, it is mandatory to draw attention to the
problem of cancer among people with SMI, both in terms of screening,
incidence and mortality as well as palliative care. The time has come for
psycho-oncology to take into consideration these issues and to launch a
campaign, through a special issue of the Journal, to analyze in detail the
various and complex aspects regarding this area of urgent clinical need.
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